Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

Gene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 trial in kidney disorder primary hyperoxaluria type 1 (PH1) last year. Lumasiran is the ...

John Abraham was born in Bombay, Maharashtra. He started his career as modelling in the music video of the song, Surma. He made his debut with Jism in 2003 opposite Bipasha Basu. He made a mark on ...

Sir John Major has blasted the previous government's Rwanda scheme as 'un-Conservative and un-British', claiming the policy was not fit for the 21st century. The former prime minister said he ...